Renaissance Technologies LLC Invests $1.68 Million in Syros Pharmaceuticals Inc (SYRS) Stock

Renaissance Technologies LLC bought a new stake in Syros Pharmaceuticals Inc (NASDAQ:SYRS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 164,900 shares of the company’s stock, valued at approximately $1,684,000.

A number of other hedge funds have also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company raised its stake in Syros Pharmaceuticals by 299.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after purchasing an additional 9,691 shares during the last quarter. Rhumbline Advisers raised its stake in Syros Pharmaceuticals by 87.6% in the 2nd quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock valued at $229,000 after purchasing an additional 10,494 shares during the last quarter. Citadel Advisors LLC acquired a new position in Syros Pharmaceuticals in the 2nd quarter valued at about $186,000. Bank of New York Mellon Corp raised its stake in Syros Pharmaceuticals by 36.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 70,592 shares of the company’s stock valued at $720,000 after purchasing an additional 19,005 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in Syros Pharmaceuticals by 7,084.0% in the 2nd quarter. Acadian Asset Management LLC now owns 28,233 shares of the company’s stock valued at $288,000 after purchasing an additional 27,840 shares during the last quarter. 60.70% of the stock is owned by hedge funds and other institutional investors.

SYRS opened at $7.09 on Monday. The stock has a market capitalization of $238.61 million, a price-to-earnings ratio of -3.33 and a beta of -1.96. Syros Pharmaceuticals Inc has a 12 month low of $6.30 and a 12 month high of $17.50.



Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Friday, August 10th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07. The business had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $1.33 million. As a group, equities research analysts forecast that Syros Pharmaceuticals Inc will post -1.85 earnings per share for the current fiscal year.

Several research analysts recently weighed in on the stock. BidaskClub downgraded shares of Syros Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 17th. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. HC Wainwright reissued a “hold” rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a research note on Wednesday, August 8th. Cann restated a “buy” rating and issued a $26.00 price target on shares of Syros Pharmaceuticals in a report on Tuesday, August 7th. Finally, Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a report on Tuesday, July 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $20.00.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

See Also: Balance Sheet

Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals Inc (NASDAQ:SYRS).

Institutional Ownership by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply